Silverback Therapeutics, Inc. (NASDAQ:SBTX – Get Free Report) was up 6.5% during trading on Thursday. The stock traded as high as $4.4350 and last traded at $4.40. Approximately 1,274,704 shares changed hands during mid-day trading, an increase of 277% from the average session volume of 337,931 shares. The stock had previously closed at $4.13.
Silverback Therapeutics Stock Down 4.4%
The stock has a market cap of $148.56 million, a price-to-earnings ratio of -1.70 and a beta of 0.60. The firm’s 50 day moving average is $5.30 and its two-hundred day moving average is $7.27.
Silverback Therapeutics Company Profile
Silverback Therapeutics, Inc was a clinical-stage biopharmaceutical company focused on developing targeted medicines for cancer and other serious diseases. The company’s research centered on its ImmunoTAC platform, which was designed to combine antibody-based targeting with therapeutic payloads to selectively modulate disease-related pathways in specific tissues.
Silverback developed an investigational pipeline of biologic and immunology-focused drug candidates intended to address areas including oncology, fibrosis and other conditions involving abnormal immune or tissue signaling.
Further Reading
- Five stocks we like better than Silverback Therapeutics
- Plexus Is Booming—But Can the Growth Story Last?
- Conagra’s Turnaround Is Starting to Show Up in the Numbers
- MarketBeat Week in Review – 09/28 – 10/02
- AST SpaceMobile’s BlueBird Progress Comes With Several Risks Still Unresolved
Receive News & Ratings for Silverback Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silverback Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
